新型药物在白癜风治疗中的应用  

Novel drugs in the treatment of vitiligo

作　　者：杨鑫 吴一菲[1] YANG Xin;WU Yifei(The First People’s Hospital of Yunnan Province,Kunming 650032,Yunnan)

机构地区：[1]云南省第一人民医院,云南昆明650032

出　　处：《皮肤病与性病》2024年第4期222-229,241,共9页Dermatology and Venereology

基　　金：国家自然科学基金项目(81860550);云南省“万人计划”名医人才专项(YNWR-MY-2019-045)。

摘　　要：白癜风是以局限性或泛发性的皮肤黏膜色素减退或脱失为特征的皮肤病,任何年龄及身体部位均可发病,多见于青年期,全球发病率可达0.1%~2%。易于诊断但难以治疗,传统的激素治疗、局部外用药物治疗和激光治疗能在一定程度上控制病情,但治疗效果仍不太令人满意,由于白癜风通常病程长、频繁复发,以及部分患者治疗抵抗或发生药物不良反应等原因,挖掘发现新型药物治疗白癜风显然是必要的,虽然目前白癜风的发病机制尚未明确,但从免疫机制干预白癜风病情的疗法已经得到越来越多的关注。本文对近年来白癜风靶向免疫治疗方面的新型药物进行综述,为白癜风的临床治疗提供参考。Vitiligo is a skin disease characterized by localized or generalized hypopigmentation or depigmentation of the skin mucous membrane,and can occur at any age and body parts,mostly in youth,with a global incidence of up to 0.1%~2%.Easy to diagnose but difficult to treat,traditional hormone therapy,local topical drug therapy and laser therapy can control the condition to a certain extent,but the therapeutic effect is still not satisfactory.Due to vitiligo usually has a long course of the disease,frequent recurrence,as well as some of the patients treatment resistance or adverse drug reactions,it is obviously necessary to discover new drugs to treat vitiligo.Although the pathogenesis of vitiligo has not yet been clarified,more and more attention has been paid to the intervention of vitiligo by immune mechanism.In this paper,we review the targeted immunotherapy of vitiligo in recent years to provide reference for the clinical treatment of vitiligo.

关 键 词：白癜风 免疫机制 JAK抑制剂 细胞因子 小分子治疗 

分 类 号：R758.41[医药卫生—皮肤病学与性病学]